Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2008

View Archived Issues

Novel transglycosylase inhibitors with antibacterial activity discovered

Eisai updates Q3 progress

Intercell to develop tuberculosis vaccine formulated with adjuvant IC-31

FDA accepts Y's Therapeutics' IND application to conduct a phase I clinical trial of YSCMA

Fornix reports results from phase II/III AB0602 clinical study of Oralgen

DiaMedica reports positive results from preclinical study of DM-99

Pharmaxis to apply for MAA in Australia for Bronchitol for the treatment of bronchiectasis

Alvine initiates dosing in phase I clinical trial of ALV-003 for celiac disease

New therapeutic agents for urinary incontinence imparted in recent Takeda patents

Recent patents report new agents for neurological disorders

Novel analgesic agents described in recent patent literature

AstraZeneca announces creation of a new company Albireo

Biogen Idec and Cardiokine initiate a phase III study of lixivaptan

DelSite initiates production of clinical quantities of nasal powder bird flu vaccine

TorreyPines presents 2008 strategic plan for tezampanel, NGX-426, and NGX-267

Migenix provides pipeline update

Neuroprotective effects of lithium in preclinical and clinical studies of ALS

VRX-496 affects HIV replication in phase II trial

Activity of RDEA-806 less affected by human serum proteins than other NNRTIs

Improved body composition seen with tesamorelin in HIV-associated lipohypertrophy

FDA approves Abbott's Simcor, a combination therapy for cholesterol management

Vaccinex licenses human anti-interleukin-6 antibody to GlaxoSmithKline

JADO reports proof of concept with lipid raft modulator in atopic dermatitis patients

Canada approves Wellbutrin XL for prevention of seasonal major depressive illness

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...